Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
Bone Disorders01:29

Bone Disorders

3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Bone Remodeling01:40

Bone Remodeling

38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

3.2K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
3.2K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV.

Journal of the American Board of Family Medicine : JABFM·2025
Same author

Cold Water Immersion for Muscle Soreness.

American family physician·2025
Same author

A new standard for treatment of torus fractures of the wrist?

The Journal of family practice·2023
Same author

Is combination pharmacotherapy effective for patients with acute depression?

The Journal of family practice·2023
Same author

Magnetic Resonance Imaging for Diagnosing Acute Appendicitis.

American family physician·2023
Same author

Time to consider topical capsaicin for acute trauma pain?

The Journal of family practice·2022

Related Experiment Video

Updated: Jun 17, 2025

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

468

Shoring Up Osteoporosis Management: A Fresh Start?

Noah Furr1, Ansley Ulmer1, Brock Cardon2

  • 1From the Nellis Family Medicine Residency, Nellis AFB, Las Vegas, NV.

Journal of the American Board of Family Medicine : JABFM
|August 14, 2024
PubMed
Summary
This summary is machine-generated.

Anabolic bone agents, including parathyroid hormone receptor agonists and sclerostin inhibitors, show greater effectiveness in preventing fractures in women with osteoporosis compared to bisphosphonates.

Keywords:
Anabolic Bone AgentsBisphosphonatesFracture PreventionOsteoporosis

More Related Videos

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.2K
Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
03:56

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention

Published on: April 26, 2024

558

Related Experiment Videos

Last Updated: Jun 17, 2025

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

468
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.2K
Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
03:56

Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention

Published on: April 26, 2024

558

Area of Science:

  • Bone biology and pharmacology
  • Osteoporosis treatment strategies
  • Clinical fracture prevention

Background:

  • Bisphosphonates are a common treatment for osteoporosis.
  • Severe osteoporosis poses a significant fracture risk.
  • Need for superior fracture prevention agents is critical.

Purpose of the Study:

  • To compare the efficacy of anabolic bone agents versus bisphosphonates.
  • To evaluate fracture prevention in women with varying osteoporosis severity.
  • To assess specific anabolic agents: parathyroid hormone receptor agonists and sclerostin inhibitors.

Main Methods:

  • Comparative analysis of anabolic agents (teriparatide, abaloparatide, romosozumab) and bisphosphonates.
  • Focus on prevention of clinically significant and vertebral fractures.
  • Study population includes women with and without severe osteoporosis.

Main Results:

  • Anabolic bone agents demonstrated superior fracture prevention.
  • Effectiveness observed in both severe and non-severe osteoporosis cases.
  • Specific agents like teriparatide, abaloparatide, and romosozumab outperformed bisphosphonates.

Conclusions:

  • Anabolic bone agents represent a more effective therapeutic option for fracture prevention in osteoporosis.
  • These agents offer improved outcomes over bisphosphonates, particularly in high-risk populations.
  • Further research may explore optimal sequencing and combination therapies.